New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision outcomes, as well as decreasing treatment burden by an 81-98% reduction in mean annualized anti-VEGF injections
- The 2x10^11 vg/eye (2E11) dose meaningfully reduced fluid volume, including a 93% reduction in intraretinal (IRF) and 55% reduction in subretinal fluid (SRF) from baseline to week 48
- The Phase 2 LUNA trial of Ixo-vec is underway, evaluating the 2E11 and 6x10^10 vg/eye (6E10) dose with enhanced prophylactic steroid regimens for the treatment of wet AMD subjects
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.